BRCA carriers and VUS patients tended to be luminal B subtypes, whereas the most common tumor subtype of non‐carriers was TNBC (27.4%), followed by the HER2‐negative luminal‐B subtype (21.6%). Here, ERBB2 is linked to neoplasm.